# Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer

> **NCT07498400** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Xijing Hospital** · enrollment: 216 (actual)

## Conditions studied

- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Breast Cancer

## Interventions

- **PROCEDURE:** Exemption of SLNB

## Key facts

- **NCT ID:** NCT07498400
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2030-12-31
- **Final completion:** 2031-03-01
- **Target enrollment:** 216 (ACTUAL)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07498400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07498400, "Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT07498400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*